Long Non-Coding RNAs in Diagnosis, Treatment, Prognosis, and Progression of Glioma: A State-of-the-Art Review.
Long Non-Coding RNAs in Diagnosis, Treatment, Prognosis, and Progression of Glioma: A State-of-the-Art Review.
复制标题
DOI：
10.3389/fonc.2021.712786
复制
发表时间：
2021
影响因子：
4.7
通讯作者：
Rezaei N
中科院分区：
文献类型：
--
作者：
Momtazmanesh S;Rezaei N
胶质瘤是最常见的恶性中枢神经系统肿瘤，死亡率和发病率都很高。尽管取得了相当大的进展，但参与肿瘤进展的确切分子途径尚未完全阐明，患者通常面临不良预后。长链非编码rna （lncRNAs）由于其在不同类型的癌症和非恶性疾病中的潜在作用，最近引起了人们的特别关注。据报道，超过200种lncrna与胶质瘤有关。我们旨在评估研究最多的lncrna在肿瘤进展的不同阶段及其介导的分子途径中的作用以及它们的临床应用。lncrna参与肿瘤形成、侵袭和进展的不同阶段，包括调节细胞周期、凋亡、自噬、上皮-间质转化、肿瘤干性、血管生成、血-瘤-脑屏障的完整性、肿瘤代谢和免疫反应。已知的在胶质瘤中表达上调的致癌lncrna有H19、HOTAIR、PVT1、UCA1、XIST、CRNDE、FOXD2-AS1、ANRIL、HOXA11-AS、TP73-AS1和DANCR。另一方面，MEG3、GAS5、CCASC2和TUSC7是肿瘤抑制lncrna，它们被下调。虽然大多数研究报道了MALAT1、TUG1和NEAT1的致癌作用，但关于这些lncrna存在一些争议。lncrna的表达水平与肿瘤分级、生存、治疗反应（化疗药物或放疗）以及整体预后相关。此外，循环中lncrna的水平，如MALAT1、H19、HOTAIR、NEAT1、TUG1、GAS5、LINK-A和TUSC7，可以提供无创诊断和预后工具。利用反义寡核苷酸调节lncRNAs的表达可以带来新的治疗方法。值得注意的是，开发新的治疗靶点需要深入了解lncrna功能的潜在分子途径。为了扩大我们对lncrna在胶质瘤中的潜在作用和应用的理解，需要更多的大样本量的研究和对体内模型的更多关注。
Glioma is the most common malignant central nervous system tumor with significant mortality and morbidity. Despite considerable advances, the exact molecular pathways involved in tumor progression are not fully elucidated, and patients commonly face a poor prognosis. Long non-coding RNAs (lncRNAs) have recently drawn extra attention for their potential roles in different types of cancer as well as non-malignant diseases. More than 200 lncRNAs have been reported to be associated with glioma. We aimed to assess the roles of the most investigated lncRNAs in different stages of tumor progression and the mediating molecular pathways in addition to their clinical applications. lncRNAs are involved in different stages of tumor formation, invasion, and progression, including regulating the cell cycle, apoptosis, autophagy, epithelial-to-mesenchymal transition, tumor stemness, angiogenesis, the integrity of the blood-tumor-brain barrier, tumor metabolism, and immunological responses. The well-known oncogenic lncRNAs, which are upregulated in glioma, are H19, HOTAIR, PVT1, UCA1, XIST, CRNDE, FOXD2-AS1, ANRIL, HOXA11-AS, TP73-AS1, and DANCR. On the other hand, MEG3, GAS5, CCASC2, and TUSC7 are tumor suppressor lncRNAs, which are downregulated. While most studies reported oncogenic effects for MALAT1, TUG1, and NEAT1, there are some controversies regarding these lncRNAs. Expression levels of lncRNAs can be associated with tumor grade, survival, treatment response (chemotherapy drugs or radiotherapy), and overall prognosis. Moreover, circulatory levels of lncRNAs, such as MALAT1, H19, HOTAIR, NEAT1, TUG1, GAS5, LINK-A, and TUSC7, can provide non-invasive diagnostic and prognostic tools. Modulation of expression of lncRNAs using antisense oligonucleotides can lead to novel therapeutics. Notably, a profound understanding of the underlying molecular pathways involved in the function of lncRNAs is required to develop novel therapeutic targets. More investigations with large sample sizes and increased focus on in-vivo models are required to expand our understanding of the potential roles and application of lncRNAs in glioma.
登录
查看更多内容
影响因子：
4
作者：
Cai T;Liu Y;Xiao J
通讯作者：
Xiao J
影响因子：
5.5
作者：
El-Fattah AAA;Sadik NAH;Shaker OG;Mohamed Kamal A;Shahin NN
通讯作者：
Shahin NN
胶质母细胞瘤词干样细胞中印迹DLK1-DIO3区域的放松调节表达：lncRNA MEG3的肿瘤抑制作用。
影响因子：
15.9
作者：
Buccarelli M;Lulli V;Giuliani A;Signore M;Martini M;D'Alessandris QG;Giannetti S;Novelli A;Ilari R;Giurato G;Boe A;Castellani G;Spartano S;Marangi G;Biffoni M;Genuardi M;Pallini R;Marziali G;Ricci-Vitiani L
通讯作者：
Ricci-Vitiani L
影响因子：
4
作者：
Cui, Bingzhou;Li, Baoshan;Cui, Youqiang
通讯作者：
Cui, Youqiang
影响因子：
8.5
作者：
Chen, Yangzong;Bao, Chunchun;Wang, Zhiqiang
通讯作者：
Wang, Zhiqiang